Mrs Donna Frede Vinal, CNM PHD | |
600 Peter Jefferson Pkwy, Suite 300, Charlottesville, VA 22911-8835 | |
(434) 293-9800 | |
(434) 977-0088 |
Full Name | Mrs Donna Frede Vinal |
---|---|
Gender | Female |
Speciality | Midwife |
Location | 600 Peter Jefferson Pkwy, Charlottesville, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083671598 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163W00000X | Registered Nurse | VA0001096715 (Virginia) | Secondary |
176B00000X | Midwife | VA0017000483 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Donna Frede Vinal, CNM PHD 600 Peter Jefferson Pkwy, Suite 300, Charlottesville, VA 22911-8835 Ph: (434) 293-9800 | Mrs Donna Frede Vinal, CNM PHD 600 Peter Jefferson Pkwy, Suite 300, Charlottesville, VA 22911-8835 Ph: (434) 293-9800 |
News Archive
Zimbabwe on Friday lifted an almost three-month ban on the work of aid groups in the country, which the government had imposed because it said some of the groups had supported the opposition to President Robert Mugabe, the New York Times reports (Dugger, New York Times, 8/30).
For the first time, researchers have analyzed the multitude of microorganisms residing in the human gut as a complex, integrated biological system, rather than a set of separate species. Their approach has revealed patterns that correspond with excess body weight.
Too much of a protein already associated with prostate cancer appears to also diminish the energy burning power of brown fat, scientists report.
Today Claritas Genomics and Genetic Alliance announced a partnership to help patients and families find and participate in relevant research opportunities that will advance understanding of individual genetic disorders and development of new therapies.
Biothera researchers have broadened their understanding of a biomarker that may enable doctors to predict which cancer patients will best respond to Imprime PGG®, the company's immunotherapy in Phase 3 drug development for colorectal cancer.
› Verified 5 days ago